Tilomisole
![]() | |
Names | |
---|---|
IUPAC name
[3-(4-Chlorophenyl)[1,3]thiazolo[3,2-a]benzimidazol-2-yl]acetic acid | |
Identifiers | |
3D model (JSmol) |
|
ChEMBL | |
ChemSpider | |
KEGG | |
PubChem CID |
|
UNII | |
| |
| |
Properties | |
C17H11ClN2O2S | |
Molar mass | 342.80 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
Infobox references | |
Tilomisole (WY-18,251) is an experimental drug which acts as an immunomodulator and has been studied for the treatment of some forms of cancer.[1][2]
It can also be seen to contain the arylacetic acid moiety that is endemic to many NSAIDs, e.g. ibufenac.
References
- ↑ Fenichel RL, Alburn HE, Schreck PA, Bloom R, Gregory FJ (1980). "Immunomodulating and antimetastatic activity of 3-(p-chlorophenyl) thiazolo[3,2-a]benzimidazole-2-acetic acid (Wy-18,251, NSC 310633)". Journal of Immunopharmacology. 2 (4): 491–508. PMID 6970786.
- ↑ Dillman RO, Ryan KP, Dillman JB, Shawler DL, Maguire R (March 1992). "WY 18,251 (Tilomisole), an analog of levamisole: tolerability, and immune modulating effects in cancer patients". Molecular Biotherapy. 4 (1): 10–4. PMID 1385709.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.